FY2026 EPS Forecast for Omnicell Increased by Analyst

Omnicell logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research raised Omnicell’s FY2026 EPS estimate to $1.73 from $1.49, above the $1.64 consensus, and maintains a Strong Buy rating.
  • The firm cut its out-year forecasts, lowering FY2027 EPS to $1.17 from $1.27 and FY2028 to $1.33 from $1.73, tempering the near-term upgrade.
  • Omnicell reported quarterly EPS of $0.58, beating the $0.42 estimate, while revenue of $307.85 million also topped expectations; revenue was down 0.9% year over year.
  • Five stocks we like better than Omnicell.

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Analysts at Zacks Research raised their FY2026 earnings estimates for Omnicell in a research report issued on Tuesday, November 17th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.73 for the year, up from their prior forecast of $1.49. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Omnicell's current full-year earnings is $1.64 per share. Zacks Research also issued estimates for Omnicell's Q4 2026 earnings at $0.23 EPS, Q1 2027 earnings at $0.24 EPS, Q2 2027 earnings at $0.24 EPS, Q3 2027 earnings at $0.29 EPS, Q4 2027 earnings at $0.40 EPS, FY2027 earnings at $1.17 EPS, Q1 2028 earnings at $0.31 EPS, Q2 2028 earnings at $0.32 EPS, Q3 2028 earnings at $0.33 EPS and FY2028 earnings at $1.33 EPS.

Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, July 31st. BTIG Research reaffirmed a "neutral" rating on shares of Omnicell in a research note on Friday, November 13th. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 7th. KeyCorp reiterated an "overweight" rating on shares of Omnicell in a research note on Monday, August 24th. Finally, Piper Sandler reissued an "overweight" rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $57.86.

Read Our Latest Stock Report on Omnicell

Omnicell Price Performance

Shares of Omnicell stock opened at $34.66 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. The firm's 50-day simple moving average is $35.11 and its 200-day simple moving average is $38.20. Omnicell has a twelve month low of $31.75 and a twelve month high of $55.00. The firm has a market cap of $1.59 billion, a P/E ratio of 36.10, a price-to-earnings-growth ratio of 0.85 and a beta of 0.88.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.16. The company had revenue of $307.85 million for the quarter, compared to the consensus estimate of $304.44 million. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The business's revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.51 EPS.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMCL. BlackRock Inc. bought a new stake in Omnicell during the 2nd quarter worth approximately $313,044,000. First Light Asset Management LLC bought a new position in Omnicell in the first quarter valued at approximately $16,351,000. Fort Washington Investment Advisors Inc. OH acquired a new position in shares of Omnicell in the third quarter valued at approximately $15,620,000. Empowered Funds LLC boosted its holdings in shares of Omnicell by 4,229.9% in the first quarter. Empowered Funds LLC now owns 262,043 shares of the company's stock valued at $8,747,000 after buying an additional 255,991 shares during the period. Finally, EVR Research LP acquired a new position in shares of Omnicell in the third quarter valued at approximately $6,470,000. Institutional investors own 97.70% of the company's stock.

Key Stories Impacting Omnicell

These are some of the OMCL stories that stood out recently:

  • Positive Sentiment: Zacks raised its FY2026 EPS estimate to $1.73 from $1.49, above the $1.64 consensus, and lifted its Q4 2026 forecast to $0.23 from $0.07. It also made a modest increase to its Q2 2027 estimate, to $0.24 from $0.23. Omnicell analyst-estimate report
  • Negative Sentiment: The analyst cut its FY2027 EPS forecast to $1.17 from $1.27 and FY2028 to $1.33 from $1.73. It also lowered estimates for several 2027–2028 quarters, including Q4 2027 to $0.40 from $0.47 and Q3 2028 to $0.33 from $0.46. These broader out-year reductions signal a weaker earnings outlook and may offset the near-term upgrades. Omnicell analyst-estimate report

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc. develops medication-management solutions for healthcare providers. Its products and services are designed to help manage medication storage, dispensing, inventory and workflows across healthcare settings. The company offers automated dispensing cabinets for patient-care areas, automation systems for central pharmacies, and software and analytics that support medication management. Its solutions serve hospitals, health systems, pharmacies and other care providers, including long-term and post-acute care organizations.

Read More

Earnings History and Estimates for Omnicell (NASDAQ:OMCL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omnicell Right Now?

Before you consider Omnicell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.

While Omnicell currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines